Tag: acquisitions

Vancouver, British Columbia, June 20, 2025 (GLOBE NEWSWIRE) -- Apogee Minerals Ltd. (“Apogee” or the “Company” or the “Optionee”) (TSXV: APMI) has amended the option agreement (the “Amendment Agreement”) with Eagle Plains (the “Optionor”) whereby the Optionor granted the Company the right to acquire up to an 80% interest in the Pine Channel Property (the “Property”).

GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it entered into a securities purchase agreement with an accredited investor for aggregate gross proceeds of $4.25 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for potential acquisitions, marketing and other general corporate purposes.

TORONTO, June 20, 2025 (GLOBE NEWSWIRE) -- Matador Technologies Inc. (“Matador” or the “Company”) (TSXV: MATA, OTCQB: MATAF, FSE: IU3), the Bitcoin Ecosystem Company, announces that it has entered into a media agreement with Flex Ecosystem Holding Ltd. d.b.a DroomDroom ("DroomDroom") dated effective June 11, 2025 (the "Media Agreement"), to provide investor relations services to the Company. DroomDroom will assist the Company in increasing investor interest and strengthening its strategic positioning in the digital asset space through curated media content and distribution.

PARIS, FRANCE, 20 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This recommendation is based on results from the CABINET Phase III trial presented at the European Society of Medical Oncology (ESMO) Congress 2024 and published in the New England Journal of Medicine.^3,4 A final decision on the approval in the European Union is expected in the coming months.

SINGAPORE, June 19, 2025 (GLOBE NEWSWIRE) -- OMS Energy Technologies Inc. (“OMS” or the “Company”) (Nasdaq: OMSE), a growth-oriented manufacturer of surface wellhead systems (“SWS”) and oil country tubular goods (“OCTG”) for the oil and gas industry, today provided a business update outlining its recent accomplishments as the Company prepares for its inaugural earnings call following its successful Nasdaq listing in May 2025.